Actinogen Medical Ltd has released a press release.
Resignation of Dr Bill Ketelbey as Chief Executive Officer
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- FDA Grants ACW Rare Paediatric Disease Designation in FXS
- Completion of Entitlement Offer
- Actinogen files new patent applications
- FDA IND Update
- ACW to initiate XanaFX clinical trial in Fragile X syndrome
Later from Actinogen Medical
- ACW raises an addtional $3.55m under a Shortfall Placement
- Actinogen appoints Dr Steven Gourlay as CEO
- Actinogen CEO assumes Managing Director position
- Strategic Update & Teleconference Call Notification
- Response to ASX Price Query
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical